How to use the speech recognition tool?
Gene therapy study on choroideremia : to assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in patients with a diagnosis of choroideremia.
Status of the trial: Completed
Orphan Drug Recognition: Yes
- Opening Date: 2017-06-01
- Closing Date: 2018-08-31
Inclusion: Visual Acuity between 20/200 and 20/40
Exclusion: age < 18 years
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-Eye